{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:19:53Z","timestamp":1783948793225,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-05417-w","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T09:54:30Z","timestamp":1764928470000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Temporal trends and disparities in cardiovascular disease-related mortality among adults with multiple myeloma in the United States, 1999\u20132023"],"prefix":"10.1186","volume":"26","author":[{"given":"Ying","family":"Tian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8017-6596","authenticated-orcid":false,"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"issue":"1","key":"5417_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"5417_CR2","unstructured":"American Cancer Society. Key Statistics About Multiple Myeloma. https:\/\/www.cancer.org\/cancer\/types\/multiple-myeloma\/about\/key-statistics.html. Updated Feb 28, 2025. Accessed August 2025."},{"issue":"8","key":"5417_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"key":"5417_CR4","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.","journal-title":"Nat Rev Dis Primers"},{"issue":"10068","key":"5417_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327.","journal-title":"Lancet"},{"issue":"5","key":"5417_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, Lenalidomide and dexamethasone vs. Lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53.","journal-title":"Blood Cancer J"},{"issue":"1","key":"5417_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","volume":"23","author":"C Eisfeld","year":"2023","unstructured":"Eisfeld C, Kaj\u00fcter H, M\u00f6ller L, Wellmann I, Shumilov E, Stang A. Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany. BMC Cancer. 2023;23(1):317.","journal-title":"BMC Cancer"},{"key":"5417_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221086755","volume":"13","author":"X Yin","year":"2022","unstructured":"Yin X, Fan F, Zhang B, Hu Y, Sun C. Cardiovascular-specific mortality among multiple myeloma patients: a population-based study. Ther Adv Hematol. 2022;13:20406207221086755.","journal-title":"Ther Adv Hematol"},{"issue":"Supplement 1","key":"5417_CR9","doi-asserted-by":"publisher","first-page":"6942","DOI":"10.1182\/blood-2024-210695","volume":"144","author":"VA Vardell","year":"2024","unstructured":"Vardell VA, Horns JJ, Daud AA, Sborov DW. Cardiovascular events in multiple myeloma: a retrospective review of the SEER-Medicare claims database. Blood. 2024;144(Supplement 1):6942\u20136942.","journal-title":"Blood"},{"issue":"9","key":"5417_CR10","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3324\/haematol.2018.191288","volume":"103","author":"S Bringhen","year":"2018","unstructured":"Bringhen S, Milan A, Ferri C, W\u00e4sch R, Gay F, Larocca A, et al. Cardiovascular adverse events in modern myeloma therapy - incidence and risks. A review from the European myeloma network (EMN) and Italian society of arterial hypertension (SIIA). Haematologica. 2018;103(9):1422\u201332.","journal-title":"Haematologica"},{"issue":"12","key":"5417_CR11","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.3324\/haematol.2023.282905","volume":"108","author":"A McCurdy","year":"2023","unstructured":"McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, Kaedbey R, D\u2019Souza A, Mohyuddin GR, Wildes TM, et al. Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica. 2023;108(12):3384\u201391.","journal-title":"Haematologica"},{"issue":"41","key":"5417_CR12","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, et al. : 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS): developed by the task force on cardio-oncology of the European society of cardiology (ESC). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"3","key":"5417_CR13","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4(3):e174519.","journal-title":"JAMA Oncol"},{"issue":"7","key":"5417_CR14","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11912-020-00931-w","volume":"22","author":"P Wu","year":"2020","unstructured":"Wu P, Oren O, Gertz MA, Yang EH. Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management. Curr Oncol Rep. 2020;22(7):66.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"5417_CR15","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","volume":"22","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414\u201323.","journal-title":"Leukemia"},{"issue":"11","key":"5417_CR16","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.3324\/haematol.2022.280893","volume":"107","author":"V De Stefano","year":"2022","unstructured":"De Stefano V, Larocca A, Carpenedo M, Cavo M, Di Raimondo F, Falanga A, et al. Thrombosis in multiple myeloma: risk stratification, antithrombotic prophylaxis, and management of acute events. A consensus-based position paper from an ad hoc expert panel. Haematologica. 2022;107(11):2536\u201347.","journal-title":"Haematologica"},{"issue":"41","key":"5417_CR17","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361.","journal-title":"Eur Heart J"},{"issue":"8","key":"5417_CR18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893\u2013911.","journal-title":"J Clin Oncol"},{"issue":"3","key":"5417_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41408-019-0183-y","volume":"9","author":"C Plummer","year":"2019","unstructured":"Plummer C, Driessen C, Szabo Z, Mateos MV. Management of cardiovascular risk in patients with multiple myeloma. Blood Cancer J. 2019;9(3):26.","journal-title":"Blood Cancer J"},{"key":"5417_CR20","doi-asserted-by":"crossref","unstructured":"Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907\u201318.","DOI":"10.1016\/S0140-6736(20)31187-9"},{"key":"5417_CR21","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple Cause of Death 1999\u20132023 on CDC WONDER Online Database. Released July 2024. Available from: https:\/\/wonder.cdc.gov\/mcd.html. Accessed August 2025."},{"issue":"210","key":"5417_CR22","first-page":"58781","volume":"62","author":"Office of Management and Budget","year":"1997","unstructured":"Office of Management and Budget. Revisions to the standards for the classification of federal data on race and ethnicity. Fed Regist. 1997;62(210):58781\u201390.","journal-title":"Fed Regist"},{"key":"5417_CR23","unstructured":"United States Census Bureau. Population Estimates Program. Available from: https:\/\/www.census.gov\/programs-surveys\/popest.html. Accessed August 2025."},{"key":"5417_CR24","first-page":"1","volume":"166","author":"DD Ingram","year":"2014","unstructured":"Ingram DD, Franco SJ. 2013 NCHS urban-rural classification scheme for counties. Vital Health Stat 2. 2014;166:1\u201373.","journal-title":"Vital Health Stat 2"},{"key":"5417_CR25","unstructured":"United States Census Bureau. Census Regions and Divisions of the United States. Available from: https:\/\/www2.census.gov\/geo\/pdfs\/maps-data\/maps\/reference\/us_regdiv.pdf. Accessed August 2025."},{"issue":"3","key":"5417_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","volume":"19","author":"HJ Kim","year":"2000","unstructured":"Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335\u201351.","journal-title":"Stat Med"},{"issue":"4","key":"5417_CR27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/j.0006-341X.2004.00256.x","volume":"60","author":"HJ Kim","year":"2004","unstructured":"Kim HJ, Fay MP, Yu B, Barrett MJ, Feuer EJ. Comparability of segmented line regression models. Biometrics. 2004;60(4):1005\u201314.","journal-title":"Biometrics"},{"key":"5417_CR28","unstructured":"National Cancer Institute. Joinpoint Regression Program, Version 5.1.0.0. Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute. 2023. Available from: https:\/\/surveillance.cancer.gov\/joinpoint\/. Accessed August 2025."},{"issue":"1","key":"5417_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/cam4.3568","volume":"10","author":"R Bishnoi","year":"2021","unstructured":"Bishnoi R, Xie Z, Shah C, Bian J, Murthy HS, Wingard JR, Farhadfar N. Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis. Cancer Med. 2021;10(1):70\u20138.","journal-title":"Cancer Med"},{"issue":"10","key":"5417_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.ctrv.2015.07.005","volume":"41","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. Cancer Treat Rev. 2015;41(10):827\u201335.","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"5417_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2013.099358","volume":"99","author":"M Engelhardt","year":"2014","unstructured":"Engelhardt M, Terpos E, Kleber M, Gay F, W\u00e4sch R, Morgan G, et al. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica. 2014;99(2):232\u201342.","journal-title":"Haematologica"},{"issue":"22","key":"5417_CR32","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1200\/JCO.19.00231","volume":"37","author":"RF Cornell","year":"2019","unstructured":"Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. J Clin Oncol. 2019;37(22):1946\u201355.","journal-title":"J Clin Oncol"},{"issue":"7","key":"5417_CR33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","volume":"133","author":"P Efentakis","year":"2019","unstructured":"Efentakis P, Kremastiotis G, Varela A, Nikolaou PE, Papanagnou ED, Davos CH, et al. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. Blood. 2019;133(7):710\u201323.","journal-title":"Blood"},{"issue":"1","key":"5417_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","volume":"5","author":"G Georgiopoulos","year":"2023","unstructured":"Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos IP, et al. Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: cardiooncology state-of-the-art review. JACC CardioOncol. 2023;5(1):1\u201321.","journal-title":"JACC CardioOncol"},{"issue":"7","key":"5417_CR35","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Mu\u00f1oz A, Brenner B, Prata PH, Brilhante D, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334\u201347.","journal-title":"Lancet Oncol"},{"issue":"18","key":"5417_CR36","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751\u20137.","journal-title":"J Clin Oncol"},{"issue":"24","key":"5417_CR37","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","volume":"115","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson SY, Pfeiffer RM, Bj\u00f6rkholm M, Goldin LR, Schulman S, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115(24):4991\u20138.","journal-title":"Blood"},{"issue":"15","key":"5417_CR38","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, Grogan M, Hayman SR, Kapoor P, Leung N, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111\u20139.","journal-title":"Blood"},{"issue":"8","key":"5417_CR39","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","volume":"26","author":"EV Robilotti","year":"2020","unstructured":"Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, Bogler Y, Caldararo M, Figueroa CJ, Glickman MS, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26(8):1218\u201323.","journal-title":"Nat Med"},{"issue":"2","key":"5417_CR40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jacc.2020.10.055","volume":"77","author":"RK Wadhera","year":"2021","unstructured":"Wadhera RK, Shen C, Gondi S, Chen S, Kazi DS, Yeh RW. Cardiovascular deaths during the COVID-19 pandemic in the united States. J Am Coll Cardiol. 2021;77(2):159\u201369.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"5417_CR41","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1038\/s44161-023-00220-2","volume":"2","author":"L Han","year":"2023","unstructured":"Han L, Zhao S, Li S, Gu S, Deng X, Yang L, Ran J. Excess cardiovascular mortality across multiple COVID-19 waves in the united States from March 2020 to March 2022. Nat Cardiovasc Res. 2023;2(3):322\u201333.","journal-title":"Nat Cardiovasc Res"},{"issue":"4","key":"5417_CR42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","volume":"1","author":"LJ Costa","year":"2017","unstructured":"Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the united States. Blood Adv. 2017;1(4):282\u20137.","journal-title":"Blood Adv"},{"issue":"3","key":"5417_CR43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.122.060199","volume":"146","author":"AN Kyalwazi","year":"2022","unstructured":"Kyalwazi AN, Loccoh EC, Brewer LC, Ofili EO, Xu J, Song Y, Joynt Maddox KE, Yeh RW, Wadhera RK. Disparities in cardiovascular mortality between black and white adults in the united States, 1999 to 2019. Circulation. 2022;146(3):211\u201328.","journal-title":"Circulation"},{"issue":"3","key":"5417_CR44","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jaccao.2024.05.002","volume":"6","author":"VB Sheppard","year":"2024","unstructured":"Sheppard VB, Sutton AL, Salehian S, Hines AL, Williams KP, Edmonds MC, et al. Community engagement to advance equitable Cardio-Oncology care: a call to action: JACC: cardiooncology how to. JACC CardioOncol. 2024;6(3):381\u20135.","journal-title":"JACC CardioOncol"},{"issue":"11","key":"5417_CR45","doi-asserted-by":"publisher","DOI":"10.1161\/HCQ.0000000000000123","volume":"16","author":"R Masterson Creber","year":"2023","unstructured":"Masterson Creber R, Dodson JA, Bidwell J, Breathett K, Lyles C, Harmon Still C, et al. Telehealth and health equity in older adults with heart failure: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes. 2023;16(11):e000123.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"5417_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/20552076251326233","volume":"11","author":"S Wang","year":"2025","unstructured":"Wang S, von Huben A, Sivaprakash PP, Saurman E, Norris S, Wilson A. Addressing health service equity through telehealth: a systematic review of reviews. DIGITAL HEALTH. 2025;11:20552076251326233.","journal-title":"DIGITAL HEALTH"},{"issue":"8","key":"5417_CR47","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","volume":"151","author":"SS Martin","year":"2025","unstructured":"Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Bansal N, Beaton AZ, et al. 2025 heart disease and stroke statistics: A report of US and global data from the American heart association. Circulation. 2025;151(8):e41\u2013660.","journal-title":"Circulation"},{"issue":"36","key":"5417_CR48","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European society of cardiology (ESC). Eur Heart J. 2016;37(36):2768\u2013801.","journal-title":"Eur Heart J"},{"issue":"2","key":"5417_CR49","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171\u201390.","journal-title":"Ann Oncol"},{"issue":"25","key":"5417_CR50","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","volume":"42","author":"SCORE2 risk prediction","year":"2021","unstructured":"SCORE2 risk prediction. Algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439\u201354.","journal-title":"Eur Heart J"},{"issue":"6","key":"5417_CR51","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","volume":"117","author":"RB D\u2019Agostino","year":"2008","unstructured":"D\u2019Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation. 2008;117(6):743\u201353.","journal-title":"Circulation"},{"issue":"10","key":"5417_CR52","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15(10):1063\u201393.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"22","key":"5417_CR53","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.jacc.2020.12.074","volume":"77","author":"W Jiang","year":"2021","unstructured":"Jiang W, Zhao W, Huang H. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021;77(22):2869\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"5417_CR54","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280\u201399.","journal-title":"Eur Heart J"},{"issue":"Suppl 35","key":"5417_CR55","doi-asserted-by":"publisher","first-page":"S4282","DOI":"10.21037\/jtd.2018.08.15","volume":"10","author":"L Michel","year":"2018","unstructured":"Michel L, Rassaf T, Totzeck M. Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. J Thorac Dis. 2018;10(Suppl 35):S4282\u201395.","journal-title":"J Thorac Dis"},{"issue":"4","key":"5417_CR56","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1182\/blood-2011-03-344333","volume":"119","author":"A Larocca","year":"2012","unstructured":"Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):933\u20139.","journal-title":"Blood"},{"issue":"8","key":"5417_CR57","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"5417_CR58","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2188\/jea.JE20150010","volume":"26","author":"MN Mieno","year":"2016","unstructured":"Mieno MN, Tanaka N, Arai T, Kawahara T, Kuchiba A, Ishikawa S, Sawabe M. Accuracy of death certificates and assessment of factors for misclassification of underlying cause of death. J Epidemiol. 2016;26(4):191\u20138.","journal-title":"J Epidemiol"},{"issue":"6","key":"5417_CR59","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1177\/0033354917736514","volume":"132","author":"L McGivern","year":"2017","unstructured":"McGivern L, Shulman L, Carney JK, Shapiro S, Bundock E. Death certification errors and the effect on mortality statistics. Public Health Rep. 2017;132(6):669\u201375.","journal-title":"Public Health Rep"},{"issue":"8 Suppl","key":"5417_CR60","first-page":"Iv","volume":"40","author":"JL Warren","year":"2002","unstructured":"Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the united States elderly population. Med Care. 2002;40(8 Suppl):Iv\u20133.","journal-title":"Med Care"},{"issue":"55","key":"5417_CR61","first-page":"3","volume":"2020","author":"L Enewold","year":"2020","unstructured":"Enewold L, Parsons H, Zhao L, Bott D, Rivera DR, Barrett MJ, Virnig BA, Warren JL. Updated overview of the SEER-Medicare data: enhanced content and applications. J Natl Cancer Inst Monogr. 2020;2020(55):3\u201313.","journal-title":"J Natl Cancer Inst Monogr"},{"key":"5417_CR62","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.21.00158","volume":"6","author":"AR Post","year":"2022","unstructured":"Post AR, Burningham Z, Halwani AS. Electronic health record data in cancer learning health systems: challenges and opportunities. JCO Clin Cancer Inform. 2022;6:e2100158.","journal-title":"JCO Clin Cancer Inform"},{"issue":"11","key":"5417_CR63","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil R, Mueller C, \u010celutkien\u0117 J, Henriksen PA, Lenihan D, Dent S, Barac A, Stanway S, Moslehi J, Suter TM, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology study group of the heart failure association and the Cardio-Oncology Council of the European society of cardiology. Eur J Heart Fail. 2020;22(11):1966\u201383.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"5417_CR64","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1200\/JOP.2016.018770","volume":"13","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Lenihan D. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline summary. J Oncol Pract. 2017;13(4):270\u20135.","journal-title":"J Oncol Pract"},{"issue":"4","key":"5417_CR65","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, et al. Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol. 2021;77(4):392\u2013401.","journal-title":"J Am Coll Cardiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05417-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-05417-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-05417-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:03:40Z","timestamp":1768341820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-025-05417-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5417"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-05417-w","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used publicly available, de-identified mortality data from CDC WONDER and was exempt from institutional review board approval and informed consent requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}